Reset filter
Palabras clave
Legeundersøkelse ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

789 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Vital Signs Week 1 Pre-dose (Visit 1)Ropinirole Parkinson Disease 101468/165 - Vital Signs Week 1 Pre-dose (Visit 1)

- 20/9/21 - 1 formulario, 1 itemgroup, 11 items, 1 idioma
Itemgroup: Vital Signs
Study Part: Vital Signs Week 1 Pre-dose (Visit 1). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Vital Signs Week 1 Day 1 (Visit 2) Ropinirole Parkinson Disease 101468/165 - Vital Signs Week 1 Day 1 (Visit 2)

- 20/9/21 - 1 formulario, 1 itemgroup, 10 items, 1 idioma
Itemgroup: Vital Signs
Study Part: Vital Signs Week 1 Day 1 (Visit 2). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Vital Signs Week 1 PK Visit (Visit 3) Ropinirole Parkinson Disease 101468/165 - Vital Signs Week 1 PK Visit (Visit 3)

- 20/9/21 - 1 formulario, 1 itemgroup, 11 items, 1 idioma
Itemgroup: Vital Signs
Study Part: Vital Signs Week 1 PK Visit (Visit 3). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Lebendspende NTX Befund MS University Hospital Muenster (UKM)

- 20/9/21 - 1 formulario, 3 itemgroups, 52 items, 1 idioma
Itemgroups: General information, Diagnostics of antigens and antibodies, Examinations
Hospital Routine Documentation Form at the University Hospital Muenster. Original Form name: Lebendspende NTX Befund MS.

Vital Signs Week 4 PK Visit (Visit 8) Ropinirole Parkinson Disease 101468/165 - Vital Signs Week 4 PK Visit (Visit 8)

- 20/9/21 - 1 formulario, 1 itemgroup, 11 items, 1 idioma
Itemgroup: Vital Signs
Study Part: Vital Signs Week 4 PK Visit (Visit 8). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Vital Signs Week 5 PK Visit (Visit 9) Ropinirole Parkinson Disease 101468/165 - Vital Signs Week 5 PK Visit (Visit 9)

- 20/9/21 - 1 formulario, 1 itemgroup, 11 items, 1 idioma
Itemgroup: Vital Signs
Study Part: Vital Signs Week 5 PK Visit (Visit 9). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Unscheduled Vital Signs Ropinirole Parkinson Disease 101468/165 - Unscheduled Vital Signs

- 20/9/21 - 1 formulario, 1 itemgroup, 10 items, 1 idioma
Itemgroup: Vital Signs
Study Part: Unscheduled Vital Signs. An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Visit V0 LAIS grass tablets by allergic rhinoconjunctivitis EudraCT-Nr.2012-004916-79 - Visit V0 Screening visit

- 20/9/21 - 1 formulario, 18 itemgroups, 157 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria, demographics, Laboratory, Physical examination, Medical Examination Rhinoscope, History of allergies, Clinical symptoms, Score Rhinoconjunctivitis, Concomitant medication, medical history, skin prick test, Spirometry; Peak Expiratory Flow, Conjunctival provocation testing, diagnostics allergy, Hematology, Biochemistry, Inclusion Criteria
Study part: Visit V0 Screening visit. Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Screening Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole NCT00460148

- 20/9/21 - 1 formulario, 27 itemgroups, 251 items, 1 idioma
Itemgroups: Subject Information, Demography, Child-bearing Potential (Complete for Female Subjects Only), Pregnancy Test (Complete for Female Subjects of Child-bearing Potential Only), Local Laboratory Result Data, Medical Conditions, Urine Drug Screen, Alcohol Test, Serology - HIV/Hepatitis Screen, Physical examination, History of tobacco use, Vital signs, 12-Lead ECG, 12-Lead ECG Abnormalities, 12-Lead ECG Abnormalities: A. Rhythm, 12-Lead ECG Abnormalities: B. P-Wave and QRS Morphology, 12-Lead ECG Abnormalities: C. Conduction, 12-Lead ECG Abnormalities: D. Myocardial Infarction, 12-Lead ECG Abnormalities: E. Depolarisation/Repolarisation (QRS-T), 12-Lead ECG Abnormalities: Other Abnormalities, Local laboratory result data (haematology), Local laboratory result data - (clinical chemistry), Urinalysis, Eligibility Question, Inclusion Criteria, Exclusion Criteria, Investigator Comment Log
Documentation Part: Screening An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets. ClinicalTrials.gov Identifier: NCT00460148 https://clinicaltrials.gov/ct2/show/NCT00460148?term=NCT00460148&rank=1 Responsible Party: GlaxoSmithKline

Vital Signs (VS) Ropinirole Restless Legs Syndrom NCT00355641 - Vital Signs

- 20/9/21 - 1 formulario, 4 itemgroups, 18 items, 1 idioma
Itemgroups: Vital Signs, Pre- dose, post dose, post dose
Study part: Vital Signs. A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Clinicaltrials.gov Identifier: NCT00355641. Phase: phase 3. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/206. Clinical Study ID: 101468/206.

On-Study - PHYSICAL EXAM SCREEN - 2390964v1.0 - PHYSICAL EXAM SCREEN

- 20/9/21 - 1 formulario, 2 itemgroups, 6 items, 1 idioma
Itemgroups: PHYSICAL EXAM--SCREENING, COMMENTS
Physical Exam Screening form for C3D 3.12 Adopters Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FEF2E3DC-3E2D-329B-E034-0003BA3F9857

On-Study - PHYSICAL EXAM - 2407645v1.0 - PHYSICAL EXAM

- 20/9/21 - 1 formulario, 2 itemgroups, 8 items, 1 idioma
Itemgroups: PHYSICAL EXAM, COMMENTS
Physical Exam form for C3D 3.12 Adopters Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=01603C3C-DD2D-4BA2-E044-0003BA3F9857

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial